Get the Stockscreener App
0.525
0.76%
-0.004
After Hours:
.51
-0.015
-2.86%
Matinas Biopharma Holdings Inc stock is traded at $0.525, with a volume of 33,129.
It is down -0.76% in the last 24 hours and down -18.34% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.529
Open:
$0.5146
24h Volume:
33,129
Relative Volume:
1.13
Market Cap:
$3.36M
Revenue:
$1.10M
Net Income/Loss:
$-10.96M
P/E Ratio:
-0.256
EPS:
-2.0506
Net Cash Flow:
$-7.01M
1W Performance:
+7.14%
1M Performance:
-18.34%
6M Performance:
-72.37%
1Y Performance:
-9.48%
1-Day Range:
$0.5001
$0.543
1-Week Range:
$0.48
$0.543
52-Week Range:
$0.48
$3.09
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Compare MTNB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.525 | 3.39M | 1.10M | -10.96M | -7.01M | -2.0506 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Sell Signal: Will Matinas BioPharma Holdings Inc benefit from government policy2026 Bull vs Bear & Expert Curated Trade Setups - baoquankhu1.vn
Aug Setups: Can Matinas BioPharma Holdings Inc generate free cash flow2026 Fed Impact & Verified Chart Pattern Signals - baoquankhu1.vn
Analyst Upgrade: Can Matinas BioPharma Holdings Inc ride the EV waveJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Aug Wrap: What are the risks of holding Matinas BioPharma Holdings Inc2026 Earnings Surprises & High Accuracy Trade Alerts - baoquankhu1.vn
SHPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Matinas BioPharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity and Ongoing Losses 1 - Minichart
SHPH PE Ratio & Valuation, Is SHPH Overvalued - Intellectia AI
Matinas BioPharma Faces NYSE Compliance Issues - Intellectia AI
Heritage Signs & Displays Completes JD Lewis Center Transformative Branding Project in Raleigh, NC - Weekly Voice
Matinas BioPharma Holdings, Inc. Notifies NYSE American of Non-Compliance with Continued Listing Standards - Quiver Quantitative
Matinas BioPharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline - Stock Titan
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - ChartMill
Matinas BioPharma has until May 2 to answer NYSE notice - Stock Titan
MAT2203 stakes rise as Matinas BioPharma (NYSE: MTNB) slashes staff, seeks partner - Stock Titan
Gains Recap: What are the future prospects of Matinas BioPharma Holdings IncEarnings Performance Report & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Germany Stocks: Research Stocks from Germany Stock Market - GuruFocus
TOTDY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
DBSM.SI Should I Buy - Intellectia AI
Volume Recap: Will Matinas BioPharma Holdings Inc outperform tech stocks2026 Fed Impact & AI Enhanced Trading Signals - baoquankhu1.vn
BHAT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MTNB PE Ratio & Valuation, Is MTNB Overvalued - Intellectia AI
Aug Update: Is Matinas BioPharma Holdings Inc a stock for growth or value investors2026 Pullback Review & Safe Entry Momentum Stock Tips - baoquankhu1.vn
ES=F PE Ratio & Valuation, Is ES=F Overvalued - Intellectia AI
Performance Recap: What are the future prospects of Matinas BioPharma Holdings Inc2026 Momentum & Breakout Confirmation Trade Signals - baoquankhu1.vn
Volume Recap: Whats the beta of Matinas BioPharma Holdings Inc stockTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
MTNB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Dow Update: Can Matinas BioPharma Holdings Inc keep up with sector leaders2026 Technicals & Fast Entry and Exit Trade Plans - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
002044.SZ Forecast — Price Prediction for 2026. Should I Buy 002044.SZ? - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
CLF Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving PremarketC3.ai - Benzinga
Gainers Report: How does ATHPRC correlate with NasdaqSwing Trade & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Can Matinas BioPharma Holdings Inc. ride the EV waveJuly 2025 Review & Risk Managed Trade Strategies - Mfd.ru
Is Matinas BioPharma Holdings Inc. a stock for growth or value investorsJuly 2025 Recap & Safe Capital Growth Tips - mfd.ru
Why Matinas BioPharma Holdings Inc. (6LJ0) stock is favored by hedge fundsWeekly Stock Report & High Accuracy Investment Signals - mfd.ru
Can Matinas Biopharma Holdings Inc. stock survive global slowdownWeekly Investment Report & Consistent Growth Stock Picks - mfd.ru
Entry Recap: Is Matinas BioPharma Holdings Inc exposed to currency risksJuly 2025 Catalysts & Weekly Breakout Watchlists - baoquankhu1.vn
What are the future prospects of Matinas BioPharma Holdings Inc.Trade Risk Summary & Smart Allocation Stock Tips - mfd.ru
What is Matinas BioPharma Holdings Inc. s P E ratio telling us2025 Biggest Moves & Safe Entry Zone Identification - mfd.ru
Can Matinas BioPharma Holdings Inc. stock outperform in 2025 bull market2025 Key Lessons & Weekly High Return Forecasts - mfd.ru
Merger Talk: Can Matinas BioPharma Holdings Inc ride the EV waveTrade Performance Summary & High Conviction Trade Alerts - baoquankhu1.vn
Matinas BioPharma appoints CEO Jerome Jabbour as interim CFO By Investing.com - Investing.com Nigeria
Matinas BioPharma CEO Named Interim Chief Financial Officer - The Globe and Mail
Matinas BioPharma appoints CEO Jerome Jabbour as interim CFO - Investing.com
Matinas BioPharma Holdings Inc Keith Kucinski resigns as CFO effective January 17, 2026 - marketscreener.com
Buyback Watch: Is STNG undervalued by DCF analysisBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026 - TradingView
Trend Report: Is Matinas BioPharma Holdings Inc stock heavily shortedNew Guidance & Weekly High Conviction Ideas - baoquankhu1.vn
Valuation Update: What is CRVSs book value per share2025 Year in Review & Daily Market Momentum Tracking - baoquankhu1.vn
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):